ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

43.40
-0.60
(-1.36%)
Closed December 04 4:00PM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
43.40
Bid
42.80
Ask
43.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
44.00
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
114
Financial Volume
-
VWAP
-

2GH Latest News

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus...

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.20.46296296296343.247436846.00073529DE
4-6.6-13.25051.540.49946.46118598DE
12-2-4.4052863436145.451.540.411447.6509915DE
26-3.6-7.659574468094757.540.415148.80167589DE
5220.287.068965517223.258.521.39999917044.24400398DE
15619.682.352941176523.858.51916541.98058262DE
26019.682.352941176523.858.51916541.98058262DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
P1MOrdinary Shares
0.771 €
(2,012.33%)
11.77k
BLEBluebird bio Inc
0.6568 €
(92.33%)
191.66k
PA8Paion AG
0.0184 €
(58.62%)
27.5k
9SCManganese X Energy Corp
0.0374 €
(50.81%)
54k
SQHSpearmint Resources Inc
0.017 €
(41.67%)
581.39k
4E2Relmada Therapeutics Inc
0.605 €
(-77.08%)
51.57k
L7C2Windfall Geotek Inc
0.0035 €
(-58.82%)
150.12k
R1EAEV Resources Ltd
0.0014 €
(-46.15%)
38k
BVU3St James Gold Corp
0.065 €
(-39.25%)
10k
UH7ATennant Minerals NL
0.007 €
(-39.13%)
20k
PF8European Lithium Limited
0.0318 €
(-21.67%)
24.15M
D7GNel ASA
0.2699 €
(8.92%)
7.96M
AXIAtos SE
0.3199 €
(-25.78%)
4.47M
BT81PowerHouse Energy Group Plc
0.0124 €
(0.00%)
1.85M
I5RImage Resources NL
0.059 €
(7.27%)
1.78M

Discussion

View Full Feed
Magnum7419 Magnum7419 5 minutes ago
well the numbers are in ............r they strong enough?
AHRO
RIGATONI RIGATONI 5 minutes ago
Dip heads up after hours on small financing..

LODE .39

Added a block
microcapbiotech microcapbiotech 5 minutes ago
I am hoping that by the end of the year they mean 2024 and not 2025.
I am also hoping that the "entire data set" is for like 30 or full enrollment of 37 patients and not just the same 3 patients that we have been hearing about for almost a year now.
They better come through with someth
MRKR
Donotunderstand Donotunderstand 5 minutes ago
too logical
FNMA
chumfm chumfm 5 minutes ago
Need to get over one dollar and stay there.They will be partnering up with many companies with their face recognition.Every internet company will be knocking on their door.The government will mandate this in multiple countries.Good luck and good trading.
IDAI
Richard H2 Richard H2 5 minutes ago
Absolutely. These types of stocks not only linger but thrive on theatrics like false fundraising campaigns, perpetually overpromised "breakthroughs," and a rotating door of misadventures disguised as partnerships. Astra is no different, with its history of phantom projects and alliances that exist s
ASRE
Smattchew Smattchew 6 minutes ago
but that's a different form. It's not the same one revised at all. Link me to the corrected one when it's available
longrider51 longrider51 6 minutes ago
Another yawn.
KBLB
longrider51 longrider51 6 minutes ago
Yawn...
KBLB
Jp_SHMP Jp_SHMP 6 minutes ago
the wise are buying into the gold mine
IGPK
ilovetech ilovetech 7 minutes ago
At the bottom of the so called study:
This work was funded by Moderna, Inc.

There's a fool born every minute.
NWBO
1vman 1vman 7 minutes ago
***** 🚽MJNA🚽 Short high !!! cover low !!! .0001

PEE YEW !!! Stinky OTC pinky here

Rinse and repeat

ENOUGH SAID HUZZAH 🤪!!!
MJNA
longrider51 longrider51 7 minutes ago
TRADING AT.10 AFTER MKT.You should know better than that.
Overnight Trading Eligible No
https://www.otcmarkets.com/stock/KBLB/quote#level-2
KBLB
John_Vallay John_Vallay 8 minutes ago
Cornerstone Marketing
Based on your post it is safe to say you have zero knowledge of investing or you are a dullard.
ENDV
ITradeHbu ITradeHbu 8 minutes ago
8k out, and hmbl's move today with its share structure gives me alil hope that this can move up again. just up to management 
GTCH
silkcash silkcash 8 minutes ago
Thank you, Gimmie-still not sure about the IPO
KBLB
King Bolaba King Bolaba 8 minutes ago
We had the same reaction to the video banana! :-)   I'm going to make a prediction. We will have a buyout offer next year that will be very hard to turn down! It's coming! 
KBLB
TheRealMrPirate TheRealMrPirate 9 minutes ago
https://ir.bioagelabs.com/node/7046/html

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175476001
Samuel J Samuel J 9 minutes ago
Your 1978 1939 showed up in the log as SELL and not BUY.

Typical MM manipulation.

ALL IN DUE TIME.
AZRH
stockinspector stockinspector 9 minutes ago
If everyone here is using the same sailboat (WDLF) and getting completely different results,
then how can that be explained in simple terms? I try to focus on that which I can control.
WDLF
ConstellationJoe ConstellationJoe 9 minutes ago
Even if this only bumps up to .0003 I'll be happy.
JAMN
TheRealMrPirate TheRealMrPirate 10 minutes ago
Okay__ 🤷
rosemountbomber rosemountbomber 10 minutes ago
Yeah this is crazy.  Between the scripts being denied and Ernie reminding me of the gooberment, I lightened up the other day. 43 sponsors.  Heck my SS Fairness Act has 330 sponsors and still waiting for the Senate to act.  SMH. 
ARDX
Schrodingers Cat Schrodingers Cat 10 minutes ago
Dec 4 short volumes: CODX 15%, FLGT 43%, QDEL 45%, VERU 42%.
CODX VERU

Your Recent History

Delayed Upgrade Clock